On August 30, 2018 Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, reported that Aron Knickerbocker, Chief Executive Officer, will present at the 2018 Wells Fargo Healthcare Conference, Sept. 6, 2018, at 2:30 pm ET (Press release, Five Prime Therapeutics, AUG 30, 2018, View Source [SID1234529192]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and may be accessed at the "Events & Presentations" section of the Company’s website at View Source Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

On August 30, 2018 Diplomat Pharmacy, Inc. (NYSE: DPLO), reported that executives will present at three upcoming investor conferences (Press release, Diplomat Speciality Pharmacy, AUG 30, 2018, View Source [SID1234529191]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Baird Global Healthcare Conference in New York: Atul Kavthekar, chief financial officer, will present at 9:40 a.m. ET. Sept. 5.

Wells Fargo Securities Healthcare Conference in Boston: Brian Griffin, chairman and chief executive officer, and Atul Kavthekar, chief financial officer, will present at 8 a.m. ET. Sept. 6.

Morgan Stanley Global Healthcare Conference in New York: Brian Griffin, chairman and CEO; Joel Saban, president; and Atul Kavthekar, chief financial officer, will present at 11:40 a.m. ET. Sept. 12.

Live audio webcasts of each presentation will be available on the investor relations section of Diplomat’s website at ir.diplomat.is. Recordings will be available for approximately 90 days following each presentation at the same URL.

On August 30, 2018 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported that it is scheduled to
present at the following upcoming events (Press release, Arrowhead Pharmaceuticals, AUG 30, 2018, View Source [SID1234529190]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Annual B. Riley FBR Healthcare Conference– New York, September 4, 2018
Bruce Given, M.D., Arrowhead’s chief operating officer, and Vincent Anzalone, CFA, vice president of investo relations, will participate in three panel
discussions

18th World Gastroenterologists Summit – Auckland, New Zealand, September 7-8, 2018
September 7, 09:45 a.m. NZST – Dr. Given will deliver a keynote presentation titled, "Hepatitis B in focus: New biology, new targets and real hope for finite therapy"

European Respiratory Society International Congress 2018 – Paris, September 15-19, 2018
September 16, 12:15 p.m. CEST –Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver an oral presentation titled, " Targeting

ENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis"

Antivirals: Targeting HBV and Beyond – Boston, September 25, 2018
September 25, 12:00 p.m. EDT –James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, "Using siRNA to target the HBV transcriptome"

A copy of presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website after the presentations conclude.

On August 30, 2018 ArQule, Inc. (Nasdaq: ARQL) reported that Paolo Pucci, CEO, and Dr. Brian Schwartz, CMO and Head of Research and Development, will participate in investor meetings and scientific panel discussions at the B. Riley FBR Healthcare Conference on September 4, 2018, at the New York Marriott East Side Hotel in New York City (Press release, ArQule, AUG 30, 2018, View Source [SID1234529189]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 30, 2018 ArQule, Inc. (Nasdaq: ARQL) reported that Paolo Pucci, CEO, Peter Lawrence, President and COO, Brian Schwartz, CMO and Head of R&D and Marc Schegerin, Senior Vice President and Head of Strategy, Finance and Communication, will participate in Citi’s 13th Annual Biotech Conference on September 6, 2018, at the Four Seasons Hotel in Boston, MA (Press release, ArQule, AUG 30, 2018, View Source [SID1234529188]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!